Recursion Pharmaceuticals, Inc. (RXRX) insider trading.
In Q3 2026, insiders at Recursion Pharmaceuticals, Inc. reported 10 non-derivative transactions on 10 Forms 3, 4 and 5: 0 open-market purchases and 4 sales worth $435K.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 4
- Net shares, P minus S
- -122,408
- Insiders
- 6
- Last filed
- 2026-09-16
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Borgeson Blake | Director | 3 | 0 | 3 |
| Taylor Ben R | Officer · Chief Financial Officer | 2 | 0 | 0 |
| Khan Najat | Director, Officer · CEO and President | 2 | 0 | 1 |
| Hallett David | Officer · Chief Scientific Officer | 1 | 0 | 0 |
| Li Dean Y | Director | 1 | 0 | 0 |
| Dar Zavain | Director | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-15 | Taylor Ben R | F (D) | 5,396 | $3.41 | 1,071,462 | Form 4 |
| 2026-09-08 | Khan Najat | S (D) | 22,408 | $3.52 | 2,072,890 | Form 4 |
| 2026-09-01 | Borgeson Blake | S (D) | 30,000 | $3.34 | 6,158,287 | Form 4 |
| 2026-08-17 | Taylor Ben R | F (D) | 25,018 | $3.16 | 1,076,858 | Form 4 |
| 2026-08-17 | Hallett David | F (D) | 26,657 | $3.16 | 1,043,837 | Form 4 |
| 2026-08-17 | Khan Najat | F (D) | 80,498 | $3.16 | 2,095,298 | Form 4 |
| 2026-08-04 | Borgeson Blake | S (D) | 30,000 | $3.25 | 6,188,287 | Form 4 |
| 2026-07-07 | Borgeson Blake | S (D) | 40,000 | $3.96 | 6,218,287 | Form 4 |
| 2026-07-01 | Li Dean Y | A (A) | 3,747 | $0 | 1,473,329 | Form 4 |
| 2026-07-01 | Dar Zavain | A (A) | 5,109 | $0 | 240,764 | Form 4 |
Transaction codes in this quarter
Get RXRX insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1601830&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · RXRX company page · Recursion Pharmaceuticals, Inc. on SEC.gov
Questions
Are insiders buying or selling Recursion Pharmaceuticals, Inc. (RXRX)?
In Q3 2026, insiders at Recursion Pharmaceuticals, Inc. reported 10 non-derivative transactions on 10 Forms 3, 4 and 5: 0 open-market purchases and 4 sales worth $435K. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Recursion Pharmaceuticals, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/rxrx.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.